IBM is trying to rebound after results disappointed initially. What analysts and investors are saying

IBM reported a Q3 earnings and revenue beat, yet underlying metrics revealed decelerating growth in its Red Hat and transaction processing segments, leading to an 8% intraday stock dip. Analysts are largely divided, with some expressing concern over potential 2026 headwinds from challenging mainframe comparisons and software performance, while others maintain buy ratings, citing IBM's strategic pivot to higher-margin software, strong free cash flow, AI exposure, and management's raised F25 guidance for revenue and profit. This divergence reflects ongoing debate about IBM's long-term growth trajectory.

Analysis

IBM reported a third-quarter earnings and revenue beat, yet underlying metrics revealed deceleration in Red Hat and transaction processing growth, prompting analyst concern for 2026. This nuanced performance led to IBM shares trading 1% lower, after an intraday dip of 8% on Thursday, reflecting immediate investor apprehension. Some institutional investors, however, utilized the selloff to increase their positions, citing an underappreciated company transition.

Wall Street analysts remain significantly divided on IBM's outlook, particularly concerning 2026. Bearish perspectives from UBS and Morgan Stanley highlight worries about challenging year-over-year comparisons due to the strong z17 mainframe program, potential software headwinds, and the absence of material M&A tailwinds. These firms project significant downside risk, with UBS maintaining a 'sell' rating and a $210 price target, implying 30% downside.

Conversely, Bank of America and Goldman Sachs maintain 'buy' ratings, citing IBM's raised F25 guidance for over 5% constant currency revenue growth, 1%+ PTI margin expansion, and ~$14.0bn free cash flow. These analysts emphasize IBM's strategic pivot towards higher-margin software, attractive AI exposure, and consistent financial performance as drivers for a potential stock re-rating and significant upside, with Goldman Sachs setting a $350 price target.

The divergence underscores a fundamental debate regarding IBM's long-term growth trajectory versus near-term operational challenges and valuation. While management acknowledged Red Hat's deceleration, they revised F25 guidance for total revenue growth, indicating confidence in the broader strategic direction. The market's mixed reaction reflects this ongoing tension between headline beats and underlying segment performance, creating a complex risk-reward profile.

Key Decisions for Investors

• Monitor IBM's Red Hat and transaction processing segment performance closely for signs of re-acceleration, as these are key indicators of underlying software strength.
• Evaluate the sustainability of IBM's raised F25 guidance, particularly the free cash flow generation and software margin expansion, against potential 2026 headwinds from challenging mainframe comparisons.
• Consider the long-term strategic pivot towards higher-margin software and AI exposure, weighing it against current valuation multiples and the divided analyst sentiment.